Pathophysiology and Role of the Gastrointestinal System in Spondyloarthritides

Rheumatic Disease Clinics of North America

Volumn 38, Issue 3, 2012, Pages 569-582

  Jacques, Peggy ^a   van Praet, Liesbet ^a   Carron, Philippe ^a   Van den Bosch, Filip ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Ankylosing spondylitis; Inflammatory bowel disease; Pathophysiology

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA4BETA7 INTEGRIN; ANTIINFLAMMATORY AGENT; BASILIXIMAB; BRIAKINUMAB; CELECOXIB; CERTOLIZUMAB PEGOL; DACLIZUMAB; ETANERCEPT; ETORICOXIB; FONTOLIZUMAB; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; LYMPHOCYTE ANTIGEN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PF 547659; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ADAPTIVE IMMUNITY; ARTHRITIS; COHORT ANALYSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG CONTRAINDICATION; ENTERITIS; ENVIRONMENTAL FACTOR; FEEDBACK SYSTEM; GASTROINTESTINAL TRACT; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; HISTOPATHOLOGY; HLA 27 GENE; HUMAN; IL 17 GENE; IL 23 GENE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MICROBIOME; MICROSCOPY; NONHUMAN; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SPONDYLARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; CAUSALITY; COMORBIDITY; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84867811461     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.012     Document Type: Review

References (87)

1. Mielants H., Veys E.M., Cuvelier C., et al. The evolution of spondylarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995, 22:2273-2278.
2. Peeters H., Vander Cruyssen B., Laukens D., et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004, 63:1131-1134.
3. Davis P., Thomson A.B.R., Lentle B.C. Quantitative sacroiliac scintigraphy in patients with Crohn's disease. Arthritis Rheum 1978, 21:234-237.
4. Cuvelier C., Barbatis C., Mielants H., et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987, 28:394-401.
5. Felder J.B., Korelitz B.I., Rajapakse R., et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000, 95:1949-1954.
6. Mahadevan U., Loftus E.V., Tremaine W.J., et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002, 97:910-914.
7. Matuk R., Crawford J., Abreu M.T., et al. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:352-356.
8. Takeuchi K., Smale S., Premchand P., et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196-202.
9. Reinisch W., Miehsler W., Dejaco C., et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003, 17:1371-1380.
10. Biancone L., Tosti C., Geremia A., et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004, 19:755-764.
11. Sandborn W.J., Stenson W.F., Brynskov J., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006, 4:203-211.
12. El Miedany Y., Youssef S., Ahmed I., et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006, 101:311-317.
13. Mielants H., Veys E. Ankylosing spondylitis and reactive arthritis: pathogenic aspects and therapeutic consequences 1988, Ghent University, Ghent.
14. Reveille J.D. Genetics of spondyloarthritis-beyond the MHC. Nat Rev Rheumatol 2012, 8:296-304.
15. Thjodleifsson B., Geirsson A.J., Bjornsson S., et al. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007, 56:2633-2639.
16. Rutgeerts P., Vermeire S. Serological diagnosis of inflammatory bowel disease. Lancet 2000, 356(9248):2117-2118.
17. Hoffman I.E.A., Demetter P., Peeters M., et al. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003, 62:455-459.
18. de Vries M., van der Horst-Bruinsma I., van Hoogstraten I., et al. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol 2010, 37:2340-2344.
19. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
20. Ott S.J., Musfeldt M., Wenderoth D.F., et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53:685-693.
21. Frank D.N., St Amand A.L., Feldman R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 104:13780-13785.
22. Friswell M., Campbell B., Rhodes J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver 2010, 4:295-306.
23. Tannock G.W. The bowel microbiota and inflammatory bowel diseases. Int J Inflam 2010, 2010:954051.
24. Kang S., Denman S.E., Morrison M., et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010, 16:2034-2042.
25. Frye M., Bargon J., Lembcke B., et al. Differential expression of human alpha- and beta-defensins mRNA in gastrointestinal epithelia. Eur J Clin Invest 2000, 30:695-701.
26. Wehkamp J., Chu H., Shen B., et al. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett 2006, 580:5344-5350.
27. Wehkamp J., Salzman N.H., Porter E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005, 102:18129-18134.
28. Ciccia F., Bombardieri M., Rizzo A., et al. Over-expression of Paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. Rheumatology 2010, 49:2076-2083.
29. Cebra J.J., Periwal S.B., Lee G., et al. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol 1998, 6:13-18.
30. Glaister J.R. Factors affecting the lymphoid cells in the small intestinal epithelium of the mouse. Int Arch Allergy Appl Immunol 1973, 45:719-730.
31. Taurog J.D., Richardson J.A., Croft J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994, 180:2359-2364.
32. Rosenbaum J.T., Davey M.P. Hypothesis: time for a gut check: HLA B27 predisposes to ankylosing spondylitis by altering the microbiome. Arthritis Rheum 2011, 63(11):3195-3198.
33. Benjamin R., Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990, 11:137-142.
34. Kollnberger S., Bird L., Sun M.Y., et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002, 46:2972-2982.
35. Granfors K. Do bacterial antigens cause reactive arthritis?. Rheum Dis Clin North Am 1992, 18:37-48.
36. Salmi M., Andrew D.P., Butcher E.C., et al. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995, 181:137-149.
37. Demetter P., De Vos M., Van Huysse J.A., et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005, 64:321-324.
38. Baeten D., Demetter P., Cuvelier C.A., et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002, 196:343-350.
39. Baeten D., Kruithof E., De Rycke L., et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369.
40. Kontoyiannis D., Pasparakis M., Pizarro T.T., et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
41. Armaka M., Apostolaki M., Jacques P., et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008, 205:331-337.
42. Roulis M., Armaka M., Manoloukos M., et al. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A 2011, 108:5396-5401.
43. Baeten D., Demetter P., Cuvelier C., et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000, 59:945-953.
44. Baeten D., Van Damme N., Van den Bosch F., et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001, 60:750-755.
45. Canete J.D., Martinez S.E., Farres J., et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000, 59:263-268.
46. Johansson-Lindbom B., Agace W.W. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev 2007, 215:226-242.
47. Cepek K.L., Shaw S.K., Parker C.M., et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 1994, 372:190-193.
48. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008, 6:1370-1377.
49. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
50. Picarella D., Hurlbut P., Rottman J., et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997, 158:2099-2106.
51. Elewaut D., Van Damme N., De Keyser F., et al. Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg 1998, 61:288-294.
52. Salmi M., Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol 2001, 166:4650-4657.
53. Elewaut D., De Keyser F., Van Den Bosch F., et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998, 25:1932-1937.
54. Austrup F., Rebstock S., Kilshaw P.J., et al. Transforming growth factor-beta 1-induced expression of the mucosa-related integrin alpha E on lymphocytes is not associated with mucosa-specific homing. Eur J Immunol 1995, 25:1487-1491.
55. Brew R., West D.C., Burthem J., et al. Expression of the human mucosal lymphocyte antigen, HML-1, by T cells activated with mitogen or specific antigen in vitro. Scand J Immunol 1995, 41:553-562.
56. MacDonald J.K., McDonald J.W. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007, (1). CD006097.
57. Parikh A., Leach T., Wyant T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012, 18:1470-1479.
58. Capon F., Di Meglio P., Szaub J., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007, 122:201-206.
59. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
60. DeLay M.L., Turner M.J., Klenk E.I., et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009, 60:2633-2643.
61. Ciccia F., Bombardieri M., Principato A., et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009, 60:955-965.
62. Melis L., Vandooren B., Kruithof E., et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010, 69(3):618-623.
63. Sherlock J.P., Joyce-Shaikh B., Turner S.P., et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012, 18:1069-1076.
64. Appel H., Maier R., Wu P., et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011, 13:R95.
65. Cella M., Fuchs A., Vermi W., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
66. Wu L., Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009, 9:4-14.
67. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
68. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6:338-344.
69. Maul J., Loddenkemper C., Mundt P., et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005, 128:1868-1878.
70. Saruta M., Yu Q.T., Fleshner P.R., et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007, 125:281-290.
71. Boschetti G., Nancey S., Sardi F., et al. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17:160-170.
72. Di Sabatino A., Biancheri P., Piconese S., et al. Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010, 16:1891-1897.
73. Cao D., van Vollenhoven R., Klareskog L., et al. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004, 6:R335-R346.
74. Appel H., Wu P., Scheer R., et al. Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. J Rheumatol 2011, 38:2445-2451.
75. Ciccia F., Accardo-Palumbo A., Giardina A., et al. Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum 2010, 62:3625-3634.
76. Jacques P., Venken K., Van Beneden K., et al. Invariant natural killer T cells are natural regulators of murine spondylarthritis. Arthritis Rheum 2010, 62:988-999.
77. Van Praet L., Van den Bosch F., Mielants H., et al. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep 2011, 13:409-415.
78. Elewaut D., Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology 2009, 48:1029-1035.
79. Braun J., van den Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
80. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61:918-932.
81. Certolizumab pegol in subjects with active axial spondyloarthritis. 2012. Available at: [online]. http://clinicaltrials.gov.
82. Sieper J., Porter-Brown B., Thompson L., et al. Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2012, 71(Suppl 3):110.
83. Ustekinumab for the Treatment of Patients with Active Ankylosing Spondylitis (TOPAS). 2012. Available at: [online]. http://clinicaltrials.gov.
84. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70:1108-1110.
85. Lekpa F.K., Farrenq V., Canoui-Poitrine F., et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012, 79:47-50.
86. Song I.H., Heldmann F., Rudwaleit M., et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62:1290-1297.
87. Baraliakos X., Braun J., Laurent D.D., et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging. Arthritis Rheum 2011, 63:2486D.